Nika Pharmaceuticals, Inc. (NIKA)
| Market Cap | 422.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -76.40K |
| Shares Out | 1.05B |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,920 |
| Average Volume | 6,323 |
| Open | 0.302 |
| Previous Close | n/a |
| Day's Range | 0.302 - 0.402 |
| 52-Week Range | 0.250 - 0.957 |
| Beta | 0.12 |
| RSI | 47.73 |
| Earnings Date | Mar 27, 2026 |
About Nika Pharmaceuticals
Nika Pharmaceuticals, Inc. engages in the development and distribution pharmaceutical products for dietary supplements and antiviral drugs in the United States. The company offers ITV-1, TNG, physiolong, carotilen, fructin, dry boza, anthocylen C, hypocholestin, biodetoxin, silymaron, and solamentum products. The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika Pharmaceuticals, Inc. in May 2022. Nika Pharmaceuticals, Inc. was incorporated in 2000 and is based in Henderson, Nevada. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Nika Pharmaceuticals, Inc. (NIKA) Signed a Consultancy Agreement with MD Global Partners LLC
HENDERSON, Nev., March 06, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) announces that it has signed a consultancy agreement with MD Global Partners LLC, a leading Manhattan-based...
Nika Pharmaceuticals, Inc. (NIKA) Progress Update
HENDERSON, Nev., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) appeared on The Street Reports podcast where CEO Dimitar Savov shared the progress the company has made thus...
UPDATE - Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
Nika Pharmaceuticals, Inc. (NIKA) Markets Analysis and €8.5 Billion Projected Revenue
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) projects €8.5 Billion revenue from its distribution agreements for Nigeria, Ukraine, UAE, Iraq, Syria, and Jordan.
Nika Pharmaceuticals, Inc. (NIKA) Latest Developments
Nika Pharmaceuticals, Inc. (OTCQB: NIKA)'s report on the therapeutic effect of ITV-1 on AIDS, Cancer, Hepatitis volunteers and Nika Europe factory progress
Nika Pharmaceuticals, Inc. (NIKA) Signed a Distribution Agreement for Nigeria
Nika Pharmaceuticals, Inc. (OTCMKTS: NIKA) signed a distribution agreement for the Republic of Nigeria that can generate the company €7.9 billion revenue.
Nika Pharmaceuticals, Inc. (NIKA) Presents Its Business Strategy
HENDERSON, Nev., June 03, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NIKA) introduces its plans to develop the company into a sustainable business project that will consistently gro...
Nika Pharmaceuticals, Inc. (NIKA) Acquires a Two Million USD Production Building
HENDERSON, Nev., May 10, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NIKA) announces that it is the beneficial owner of a production building and land valued at $2,045,209, located i...
Nika Pharmaceuticals, Inc. (Nika) Acquires a Two Million USD Production Building
HENDERSON, Nev., May 10, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NIKA) announces that it is the beneficial owner of a production building and land valued at $2,045,209, located i...